Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zetalube
- Development stage
- Unknown
- Lead developer
- Bioquest Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Zetalube is an ophthalmic lubricant solution developed and marketed by Bioquest Pharmaceuticals. It is a combination product containing polyethylene glycol and propylene glycol, which function as demulcents to supplement natural tear production. By forming a protective and lubricating film over the ocular surface, Zetalube provides temporary relief from symptoms associated with dry eye syndrome, such as burning, stinging, itching, and the sensation of grittiness. The product is administered topically and is approved for marketing in India for the treatment of dry eye and related ocular lubrication conditions.
- Brand names
- Zetalube
Beyond the preview
Go deeper on Zetalube.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zetalube.